arrow
S

Silvia C. Formenti

Weill Cornell Medicine
H指数:89
被引数:4.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group

肿瘤浸润淋巴细胞与乳腺癌放疗:国际免疫肿瘤生物标志物工作组观点

2026-08-240
PRE
Determining Optimal Fractionation of Neoadjuvant Radiation in Low-Risk, Early-Stage Breast Cancer—Randomized SIGNAL Clinical Trial

确定低风险,早期乳腺癌新辅助放疗的最佳分割-随机信号临床试验

Cancers
IF4.4
2026-06-080
OA
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma
2026-01-070
OAAI
Neoadjuvant Non-Ablative SBRT Plus Immunotherapy Yields Similar Pathologic Response as Chemo-Immunotherapy in Non-Small Cell Lung Cancer

新辅助非消融SBRT联合免疫疗法在非小细胞肺癌中产生的病理反应与化疗联合免疫疗法相似

2025-07-180
PRE
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages

IL-17A分泌型γδ T细胞通过CX3CR1+巨噬细胞促进HR+HER2−乳腺癌对CDK4/CDK6抑制剂的抵抗

2025-07-070
PRE
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (vol 19, 8435, 2023)
2024-01-030
OAAI
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
2023-12-1913
OAAI